INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune(TM) Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Stock Information for INmune Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.